Market Overview

The FDA Cancelled Dynavax's Hep-B Drug ADCOM Meeting

The FDA Cancelled Dynavax's Hep-B Drug ADCOM Meeting

EDIT: This story originally stated the drug had been blocked by the FDA. The mistake has been corrected. 

Shares of Dynavax Technologies Corporation (NASDAQ: DVAX) are selling off Friday afternoon after the FDA cancelled their upcoming ADCOM meeting for their Heplisav drug. ADCOM meetings advise on whether or not to approve a drug.

The meeting was cancelled to allow time to review several outsanding issues with the drug.

This was Dynavax's second attempt at approval for Heplisav, a Hepatitis B vaccine. They were originally rejected in November of 2012. 

At time of writing, shares were down 33% to $10.60. 

Benzinga Pro subscribers were alerted to the news first. 


Posted-In: Biotech News FDA Movers General Best of Benzinga


Related Articles (DVAX)

View Comments and Join the Discussion!

Partner Center